<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422591</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0813</org_study_id>
    <secondary_id>NCI-2012-01412</secondary_id>
    <nct_id>NCT00422591</nct_id>
  </id_info>
  <brief_title>Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>Prospective Evaluation of Standard Chemotherapy Regimen of Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find out if standard chemotherapy given with
      idarubicin and Cytarabine (ara-C) can help to control AML.

      Objectives:

      To determine the complete response (CR) rate, event-free survival (EFS) and overall survival
      (OS) of patients with newly diagnosed acute myeloid leukemia (AML) receiving standard
      combination chemotherapy with Idarubicin and cytarabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ara-C and idarubicin are designed to interfere with DNA's (the genetic material of cells)
      ability to repair itself, causing cancer cells to die.

      If you are found to be eligible to take part in this study, you will receive treatment with
      idarubicin and ara-C for up to 8 cycles. One cycle lasts about 4-5 weeks. Cycles 1 and 2 are
      called induction therapy, which is used to help induce (cause) a remission. Cycles 3 to 8 are
      called consolidation therapy, which is a type of high-dose chemotherapy often given as the
      second phase of a cancer treatment.

      After Cycle 1, you will have a brief rest period of a few days, before you move on to Cycle
      2. On Day 1 of Cycle 1, you will receive cytarabine by vein as a continuous infusion over 4
      days. It will only be 3 days if you are age 60 or older. On Days 1-3 of Cycle 1, you will
      receive idarubicin by vein over 1 hour once a day.

      The dose of the study drugs you receive may be changed to help manage side effects (such as
      nausea and diarrhea) that you may experience. Medications (given by mouth or by vein), such
      as Tylenol (acetaminophen), may be given before and during treatment to help decrease the
      risk of such side effects. The study doctor will specify what these medications are.

      You will have blood drawn (about 2 teaspoons) for routine tests about once a week during
      treatment. Starting on Days 21-28, you will have bone marrow collected every 1-2 weeks to
      check the status of the disease. Blood (about 2 tablespoons) will also be drawn at least
      twice a week after each cycle of therapy (beginning about 4-6 weeks from the start of
      treatment each cycle) to check your blood counts.

      Cycle 2 will begin after your blood counts have recovered. If at the end of Cycle 1 you have
      not achieved a remission (disease has decreased), you may receive Cycle 2, which will be
      similar to Cycle 1.

      If the disease is responding to treatment after Cycle 2 (after completion of induction
      therapy), you will receive up to 6 more cycles of therapy. These cycles are called
      consolidation therapy. Consolidation therapy is a type of high-dose chemotherapy often given
      as the second phase to treat cancer. For consolidation therapy, you will receive ara-C as a
      continuous infusion over 3 days starting on Day 1 of Cycle 3. On Days 1 and 2 of Cycles 3 and
      4, you will receive idarubicin by vein over 1 hour. Your blood (about 2 tablespoons) will be
      drawn at least twice a week after each cycle to check your blood counts. Cycle 3 will begin
      after your blood counts have recovered.

      After completion of consolidation therapy, you may receive what is called maintenance
      therapy. Maintenance therapy will start after completion of consolidation therapy.
      Maintenance therapy is often given to help keep cancer in remission. It is treatment that is
      given to help the original treatment keep working. You will be told if you will have
      maintenance therapy as well as the drugs and drug schedule you will be on.

      During consolidation and/or maintenance therapy, blood (about 2 teaspoons) will be drawn for
      routine tests every 1-2 weeks. You will have bone marrow collected every 3-6 months to check
      the status of the disease.

      You may have treatment on this study for up to 8 cycles (induction and consolidation therapy)
      or more (for maintenance therapy), depending on disease response to the study drugs. If the
      disease gets worse or you experience any intolerable side effects, you will be taken off this
      study, and your study doctor will discuss other treatment options with you.

      Once your participation is over on this study, you will be followed-up with a phone call by
      the study doctor or study nurse to check on how you are doing and if you have experienced any
      intolerable side effects. The call should last about 10-15 minutes.

      This is an investigational study. Idarubicin and ara-C are both FDA approved and commercially
      available. Up to 200 patients will take part in this study. All will be enrolled at MD
      Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Complete Response (CR): Normalization of marrow (&lt; 5% blasts; &gt;10% cellularity) and of peripheral blood counts (no circulating blasts, neutrophil count &gt; 109/L, platelet count &gt; 100 x 109/L).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>from treatment initiation until treatment failure, relapse, or death</time_frame>
    <description>Event -Free Survival (EFS) EFS was calculated with Kaplan-Meier estimates. Event-free survival (EFS), defined as the time to no response to intensive induction therapy, relapse, or death of any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Until death or loss of follow-up</time_frame>
    <description>Overall Survival (OS) was calculated with Kaplan-Meier estimates. OS was calculated from the time of treatment initiation until death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>Idarubicin + Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idarubicin 12 mg/m2 IV over 1 hour daily x 3 (days 1-3). Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age &lt;60 years) or days 1-3 (age &gt; 60 years).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>1.5 g/m2 IV over 24 hours daily on day 1-4 (age &lt;60 years) or days 1-3 (age &gt; 60 years).</description>
    <arm_group_label>Idarubicin + Cytarabine</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>12 mg/m2 IV over 1 hour daily x 3 (days 1-3)</description>
    <arm_group_label>Idarubicin + Cytarabine</arm_group_label>
    <other_name>Idamycin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of 1) AML (WHO classification definition of &gt;/= 20% blasts). Patients with
             M6 AML with less than 20% blasts are eligible.

          2. Patients aged 15 to 75 years are eligible. Patients must be chemo-naïve, i.e. not have
             received any prior chemotherapy (except hydrea) for AML. They could have received
             transfusions, hematopoietic growth factors or vitamins. Temporary measures such as
             pheresis or hydrea (0.5 to 5g daily or more for up to 3 days) are allowed .

          3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2, or 3 at
             screening.

          4. Serum biochemical values with the following limits: - creatinine &lt;/= 2.0 mg/dl - total
             bilirubin &lt;/= 2.0 mg/dL, unless increase is due to hemolysis - transaminases (SG PT)
             &lt;/= 3x upper limit of normal (ULN)

          5. Ability to understand and provide signed informed consent.

        Exclusion Criteria:

          1. Subjects with Acute Promyelocytic Leukemia (APL).

          2. Presence of active systemic infection.

          3. Any coexisting medical condition that in the judgment of the treating physician is
             likely to interfere with study procedures or results.

          4. Nursing women, women of childbearing potential with positive urine pregnancy test, or
             women of childbearing potential who are not willing to maintain adequate contraception
             (such as birth control pills, intrauterine device (IUD), diaphragm, abstinence, or
             condoms by their partner) over the entire course of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Ravandi-Kashani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <results_first_submitted>February 26, 2018</results_first_submitted>
  <results_first_submitted_qc>May 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2018</results_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytarabine, Idarubicin</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Idarubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 12/2006 to 01/2017</recruitment_details>
      <pre_assignment_details>Of the 175 participants registered, six were never treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Idarubicin + Cytarabine</title>
          <description>Idarubicin 12 mg/m2 intravenously (IV) over 1 hour daily days 1-3. Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age &lt;60 years) or days 1-3 (age &gt; 60 years).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Idarubicin + Cytarabine</title>
          <description>Idarubicin 12 mg/m2 intravenously (IV) over 1 hour daily days 1-3. Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age &lt;60 years) or days 1-3 (age &gt; 60 years).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="19" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response (CR) Rate</title>
        <description>Complete Response (CR): Normalization of marrow (&lt; 5% blasts; &gt;10% cellularity) and of peripheral blood counts (no circulating blasts, neutrophil count &gt; 109/L, platelet count &gt; 100 x 109/L).</description>
        <time_frame>Up to 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Idarubicin + Cytarabine</title>
            <description>Idarubicin 12 mg/m2 intravenously (IV) over 1 hour daily days 1-3. Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age &lt;60 years) or days 1-3 (age &gt; 60 years).</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (CR) Rate</title>
          <description>Complete Response (CR): Normalization of marrow (&lt; 5% blasts; &gt;10% cellularity) and of peripheral blood counts (no circulating blasts, neutrophil count &gt; 109/L, platelet count &gt; 100 x 109/L).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Complete Response w/o Platelet Recovery</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-Free Survival (EFS)</title>
        <description>Event -Free Survival (EFS) EFS was calculated with Kaplan-Meier estimates. Event-free survival (EFS), defined as the time to no response to intensive induction therapy, relapse, or death of any cause, whichever comes first.</description>
        <time_frame>from treatment initiation until treatment failure, relapse, or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Idarubicin + Cytarabine</title>
            <description>Idarubicin 12 mg/m2 intravenously (IV) over 1 hour daily days 1-3. Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age &lt;60 years) or days 1-3 (age &gt; 60 years).</description>
          </group>
        </group_list>
        <measure>
          <title>Event-Free Survival (EFS)</title>
          <description>Event -Free Survival (EFS) EFS was calculated with Kaplan-Meier estimates. Event-free survival (EFS), defined as the time to no response to intensive induction therapy, relapse, or death of any cause, whichever comes first.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="1" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall Survival (OS) was calculated with Kaplan-Meier estimates. OS was calculated from the time of treatment initiation until death.</description>
        <time_frame>Until death or loss of follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Idarubicin + Cytarabine</title>
            <description>Idarubicin 12 mg/m2 intravenously (IV) over 1 hour daily days 1-3. Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age &lt;60 years) or days 1-3 (age &gt; 60 years).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall Survival (OS) was calculated with Kaplan-Meier estimates. OS was calculated from the time of treatment initiation until death.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="1" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events captured from the time of participant consent and will be followed to resolution or stabilization; up to 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Idarubicin + Cytarabine</title>
          <description>Idarubicin 12 mg/m2 intravenously (IV) over 1 hour daily days 1-3. Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age &lt;60 years) or days 1-3 (age &gt; 60 years).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Edema - leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hemorrhage Gastrointestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Intracerebral Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cardiac Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pain Cardiovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Sinus Bradycarida</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pain Head/Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Myelosupression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter Related Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Infection Abcess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis Knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Lung Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abscess Left Groin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecyctectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="65" subjects_affected="47" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Infection/unknown ANC</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Infection other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Opportunistic Infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Farhad Ravandi-Kashani, MD</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-7734</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

